Richard, Guilhem
De Groot, Anne S.
Steinberg, Gary D.
Garcia, Tzintzuni I.
Kacew, Alec
Ardito, Matthew
Martin, William D.
Berdugo, Gad
Princiotta, Michael F.
Balar, Arjun V.
Sweis, Randy F.
Article History
Received: 18 February 2021
Accepted: 19 April 2021
First Online: 11 May 2021
Competing interests
: ADG and WDM are senior officers and majority shareholders, and MA is an employee of EpiVax, Inc, a privately owned immunoinformatics and vaccine design company. All three of these authors are also involved in developing the Ancer pipeline. These authors acknowledge that there is a potential conflict of interest related to their relationship with EpiVax and attest that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company. GB was previously a senior officer of EpiVax Therapeutics, Inc., MFP is a senior officer and GR is currently an employee of EpiVax Therapeutics, Inc., a precision immunotherapy company and subsidiary of EpiVax, Inc. MFP and GR have equity in EpiVax Therapeutics. These authors acknowledge that there is a potential conflict of interest related to their relationship with EpiVax Therapeutics and attest that the work contained in this research report is free of any bias that might be associated with the commercial goals of the company. EpiVax, Inc. and EpiVax Therapeutics, Inc. own patents to technologies utilized by associated authors in the research reported here. RFS reports honoraria from Aduro, AstraZeneca, BMS, Exelixis, Eisai, Janssen, Mirati, Pfizer, and Puma. GDS is a member of Clinical Trial Protocol Committees for the following companies: Merck, BMS, Janssen, Cold Genesys, Pfizer, PhotoCure, Fidia, is or has been a scientific advisor/consultant within the past 5Â years for the following companies: Heat Biologics, Cold Genesys, PhotoCure, Merck, Roche/Genentech, Ciclomed, Taris Biomedical, MDxHealth, Fidia Farmaceuticals, Urogen, Ferring, Aduro, Boston Scientific, Bristol Myers Squibb, Astra Zeneca, Pfizer, Janssen, EpiVax Therapeutics, Natera, FKD, Ferring, EnGene Bio, SesenBio, BioCanCell, Nucleix, Ipsen, Combat Medical, Astellas, Fergene, Dendreon, Abbvie, Seattle Genetics, and has equity stock/options in EpiVax Therapeutics and Urogen. AVB reports equity stock/options in EpiVax Therapeutics. TIG and AK declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.